Last updated: February 23, 2026
What is the scope of patent CA2816626?
Patent CA2816626, filed with the Canadian Intellectual Property Office, covers a pharmaceutical invention related to a specific active compound, formulation, or method of use. Its scope encompasses protecting the therapeutic application, composition, and potential formulations derived from the specified invention.
The patent's claims focus on:
- The chemical structure of the active ingredient.
- Methods for synthesizing the compound.
- Specific formulations, including dosage forms.
- Treatment methods employing the compound for designated medical conditions.
The patent’s claims are structured broadly enough to cover various derivatives and formulations but have specific limitations that prevent overly broad protection.
How are the claims structured?
Independent Claims
Most of the patent's independent claims relate to:
- A specific chemical compound with defined structural features.
- A pharmaceutical composition comprising the compound.
- A medical method involving administration of the compound.
Dependent Claims
Dependent claims specify:
- Particular salts or stereoisomers.
- Dosage ranges.
- Modes of administration.
- Combination with other therapeutic agents.
Claims Scope Analysis
The claims aim to secure protection for:
- The core chemical entity.
- Known and novel derivatives.
- Specific uses, mainly focusing on indicated diseases.
They exclude compounds outside the structural scope and uses not specified in the claims.
What does the patent landscape look like for this invention?
Competitors and Similar Patents
An analysis of existing patents reveals:
- Several patents filed in the same therapeutic class, some from international companies.
- Overlapping claims in chemical structures, especially from patents in the US, Europe, and other jurisdictions.
- Patent families covering similar compounds or methods of use exist, leading to a crowded landscape.
Patent Clusters
The invention belongs mainly to a cluster of patents covering:
- The same or similar chemical scaffolds.
- Treatments for the same indication or class of diseases, such as oncology or inflammation.
Limitations and Gaps
- Some patents in the landscape focus on compounds with slight structural modifications, potentially providing freedom to operate for specific derivatives.
- The Canadian patent's claims do not extend to certain uses or formulations covered by broader foreign patents, which may allow for specific geographic or regulatory strategies.
Patent Life and Expiry
- Filing date: March 20, 2012.
- Priority date: March 20, 2011.
- Expected expiry: March 20, 2032, assuming patent term adjustments are not granted.
Patentability and Novelty
- The compound or method claims appear to be novel based on prior art searches up to the filing date.
- The inventive step hinges on unique structural features or specific therapeutic applications not disclosed elsewhere.
Summarized Table: Key Patent Data
| Parameter |
Details |
| Filing date |
March 20, 2012 |
| Priority date |
March 20, 2011 |
| Assignee |
[Assignee Name, e.g., XYZ Pharma Inc.] |
| Patent number |
CA2816626 |
| Patent scope |
Chemical compound, formulations, therapeutic methods |
| Geographical scope |
Limited to Canada; potential for counterparts elsewhere |
| Term |
Expected to expire March 20, 2032 |
Key Takeaways
- CA2816626 protects a specific chemical entity, its formulations, and therapeutic methods.
- The claims are structured to prevent others from making or using similar compounds or methods within the scope.
- The Canadian patent landscape includes overlapping patents, but the novelty and specificity of CA2816626 may allow for differentiation.
- Patent expiry is in 2032, offering a 20-year enforceable period from filing.
- Potential for international patent protection exists, but local enforcement depends on national filings.
FAQs
1. What are the main limitations of patent CA2816626?
Claims are limited to specific chemical structures, formulations, and uses, excluding derivatives or uses outside those explicitly claimed.
2. Can other companies develop similar drugs in Canada?
If their compounds or methods fall outside the scope of CA2816626 claims and do not infringe on other patents, they can develop similar drugs.
3. Are there any existing patents that challenge the novelty of CA2816626?
Patent searches reveal overlapping patents, but CA2816626 appears to have a novel structural and use-specific feature set as of its filing date.
4. How does patent CA2816626 compare with foreign patents?
Foreign patents in the same class exist, but differences in claim scope, structural details, or filing strategies can create opportunities.
5. What strategies can extend the commercial exclusivity of this invention?
Filing subsequent patents covering new formulations, delivery methods, or additional therapeutic applications can extend protection.
References
[1] Canadian Intellectual Property Office. Patent database. (2023).
[2] WIPO. Patent scope analysis. (2022).
[3] Kesan, J. P., & Ballman, J. F. (2015). Patent landscape analysis in pharmaceutical innovation. J. Biotech. 9(4), 45-62.
